Importantly, we identified a novel GRK3 inhibitor, LD2, through a chemical library screen and demonstrated its strong anti-tumor activity in vitro and in vivo in patient-derived PC cells with high GRK3 and YAP1 expressions. This evidence concerns the gene GRK3 and neoplasm.